Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Cansortium Reports Fourth Quarter and Full Year 2022 Results

      Cansortium Inc Logo (CNW Group/Cansortium Inc)

      News provided by

      Cansortium Inc

      May 01, 2023, 16:36 ET

      Share this article

      Share this article


      - Q4 Revenue up 28% YoY to $23.5 Million; FY 2022 Revenue up 34% YoY to $87.7 Million -

      - FY 2022 Cash from Operations up Significantly to $19.1 Million, Compared to Cash Used of $5.0 Million in FY 2021 -

      MIAMI, May 1, 2023 /PRNewswire/ -  Cansortium Inc. (CSE: TIUM.U) (OTCQX: CNTMF) ("Cansortium" or the "Company"), a vertically-integrated, multi-state cannabis company operating under the Fluent™ brand, today announced financial and operating results for the fourth quarter and full year ended December 31, 2022. Unless otherwise indicated, all results are presented in U.S. dollars.

      "We delivered strong revenue growth and material cash flow generation in 2022 despite a challenging backdrop for the broader cannabis industry, as well as the adverse impact we experienced in Florida from Hurricane Ian," said CEO Robert Beasley. "Within our home market of Florida, we captured meaningful market share driven in part by our cultivation improvements and new store openings over the course of 2022. In addition, our exit from Michigan last August enabled us to strategically reallocate capital and sharpen focus on our core operations.

      "Looking ahead, we expect to continue expanding our Florida footprint through new store openings, while further improving our cultivation to increase both capacity and flower quality. In Texas, we are making progress on building out operations in the state as we aim to maximize our first mover advantage as one of only three license holders in the market. We look forward to delivering another year of strong growth and cash flow generation as we continue to execute on our strategy in 2023."

      Q4 2022 Financial Highlights (vs. Q4 2021)

      • Revenue increased 28% to $23.5 million compared to $18.3 million.
      • Florida revenue increased 26% to $19.4 million compared to $15.4 million.
      • Adjusted gross profit1 was $0.7 million compared to $11.8 million, with the decrease driven by IAS 41 Addendum leading the Company to recognize income tax on biologicals that was not accounted for the first three quarters in 2022. Excluding this one-time impact, adjusted gross profit in Q4 2022 was $11.7 million.
      • Adjusted EBITDA increased 54% to $7.9 million compared to $5.1 million.

      FY 2022 Financial Highlights (vs. FY 2021)

      • Revenue increased 34% to $87.7 million compared to $65.4 million.
      • Florida revenue increased 31% to $73.2 million compared to $55.7 million.
      • Adjusted gross profit1 was $44.0 million or 50.1% of revenue, compared to $41.9 million or 64.1% of revenue.
      • Adjusted EBITDA increased 28% to $25.1 million compared to $19.6 million.
      • Cash from operations improved significantly to $19.1 million compared to ($5.0) million.
      • At December 31, 2022, the Company had approximately $8.4 million of cash and cash equivalents and $57.7 million of total debt, with approximately 314 million fully diluted shares outstanding.

      Operational Highlights

      • In Florida, Cansortium recently opened two new stores in Pensacola and one in Jacksonville Atlantic Beach, bringing its total Florida footprint to 31 stores. The Company anticipates opening an additional 3-5 new stores by the end of 2023. Three of these are already under contract and going through construction.
      • After the damage caused by Hurricane Ian in Q3 2022, the Company's Sweetwater facility is now fully operational with recent harvests reaching a record high 30%+ THC flower potency.
      • In Pennsylvania, Cansortium recently began the expansion of its Hanover dispensary to maximize the store's capacity for patients.
      • In Texas, the Company continued to make progress building out its operational footprint by hiring a President and dedicated team to run the state operations. More recently, Cansortium completed its first THC sale last week, implemented an advertising campaign to build awareness for new patients, and went under contract for a delivery center in Houston, TX.
      • Based on the Florida OMMU data over the last nine weeks, Cansortium has consistently held its position as #6 in the state in terms of THC sales and reached record levels for the week ended April 20, 2023.

       ________________________

      1  Adjusted gross profit is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates adjusted gross profit from gross profit plus (minus) the changes in fair value of biological assets, as presented in the consolidated statement of operations.


      Conference Call

      The Company will host a conference call and live audio webcast today at 4:30 p.m. Eastern time to discuss its financial and operational results, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing [email protected].

      Date: Monday, May 1, 2023
      Time: 4:30 p.m. Eastern time
      Toll-free dial-in number: (800) 319-4610
      International dial-in number: (604) 638-5340
      Conference ID: 10021840
      Link: Cansortium Conference Call

      Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Elevate IR at (720) 330-2829.

      The conference call will also be available for replay via the News & Events section of the Company's investor relations website at https://investors.getfluent.com/.

      About Cansortium Inc.

      Cansortium is a vertically-integrated cannabis company with licenses and operations in Florida, Pennsylvania and Texas. The Company operates under the Fluent™ brand and is dedicated to being one of the highest quality cannabis companies for the communities it serves. This is driven by Cansortium's unrelenting commitment to operational excellence in cultivation, production, distribution and retail. The Company is headquartered in Miami, Florida.

      Cansortium Inc.'s common shares trade on the CSE under the symbol "TIUM.U" and on the OTCQX Best Market under the symbol "CNTMF". For more information about the Company, please visit www.getfluent.com.

      Forward-Looking Information

      Certain information in this news release may constitute forward-looking information within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent the Company's expectations, estimates, and projections regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control.

      Forward-looking information is necessarily based on many opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

      For further information: www.getfluent.com.

      Company Contact
      Robert Beasley, CEO
      (850) 972-8077
      investors.getfluent.com

      Investor Relations Contact
      Sean Mansouri, CFA
      Elevate IR
      (720) 330-2829
      [email protected]

      Media Contact
      Patrick Maddox
      (501) 680-5220
      [email protected] 

      CANSORTIUM INC.






      CONSOLIDATED STATEMENTS OF FINANCIAL POSITION





      As of December 31, 2022 and December 31, 2021






      (USD '000)





















      December 31,
      2022


      December 31,
      2021

      Assets






      Current assets






      Cash



      $                   8,359


      $                  9,024

      Trade receivable



      28


      26

      Inventory, net



      8,973


      8,981

      Biological assets



      996


      3,297

      Investment held for sale



      -


      200

      Prepaid expenses and other current assets



      883


      2,007

      Total current assets



      19,239


      23,535







      Property and equipment, net



      31,743


      34,160

      Intangible assets, net



      94,291


      95,822

      Right-of-use assets, net



      30,464


      19,169

      Investment in associate



      -


      -

      Note receivable



      -


      4,886

      Deposit



      -


      2,727

      Goodwill



      1,526


      1,526

      Other assets



      768


      632

      Total assets



      $              178,031


      $              182,457







      Liabilities






      Current liabilities






      Trade payable



      6,931


      8,518

      Accrued liabilities



      5,534


      5,846

      Income taxes payable



      13,952


      2,120

      Derivative liabilities



      8,676


      3,960

      Current portion of notes payable



      741


      619

      Current portion of lease obligations



      2,123


      2,500

      Total current liabilities



      37,957


      23,563







      Liabilities held for sale



      -






      -



      Notes payable



      56,969


      53,674

      Lease obligations



      33,922


      21,091

      Deferred tax liability



      20,290


      21,563

      Other long-term liabilities



      1,333


      -

      Total liabilities



      150,471


      119,891







      Shareholders' equity






      Share capital



      180,954


      180,657

      Share-based compensation reserve



      6,395


      6,176

      Equity conversion feature



      6,677


      4,933

      Warrants



      28,939


      28,869

      Accumulated deficit



      (195,071)


      (157,648)

      Foreign currency translation reserve



      (334)


      (421)

      Total shareholders' equity attributable to Cansortium Inc. shareholders


      38,313


      57,453

      Non-controlling interests



      -


      -

      Total shareholders' equity 



      27,560


      62,566







      Total liabilities and shareholders' equity



      $              178,031


      $              182,457

      Cansortium Inc.






      Statement of operations






      For the three and twelve months ended December 30, 2022 and 2021






      (USD '000)







      Three months ended
      December 31,


      Year ended
      December 31,


      2022

      2021


      2022

      2021







      Revenue, net of discounts

      $              23,464

      $           18,284


      $               87,692

      $             65,437

      Cost of goods sold

      22,738

      6,519


      43,731

      23,488

      Adjusted gross profit (1)

      726

      11,765


      43,961

      41,949

      Adjusted gross margin (1)

      3.1 %

      64.3 %


      50.1 %

      64.1 %







      Realized fair value of increments on inventory sold

      27,645

      (6,582)


      2,622

      (21,015)

      Unrealized change in fair value of biological assets

      (22,844)

      3,085


      (9,620)

      14,853

      Gross profit

      5,527

      8,268


      36,963

      35,787

      Gross margin

      23.6 %

      45.2 %


      42.2 %

      54.7 %







      Expenses:






      General and administrative

      941

      2,085


      8,288

      10,326

      Share-based compensation

      391

      56


      545

      4,304

      Sales and marketing

      4,677

      4,322


      17,510

      15,416

      Depreciation and amortization

      1,751

      1,658


      6,765

      6,384

       Total expenses 

      7,760

      8,121


      33,108

      36,430







      Income (Loss) from operations

      (2,233)

      147


      3,855

      (643)







      Discontinued operations

      277

      1


      277

      35







      Other expense (income):






      Finance costs, net

      $                4,165

      $             4,527


      16,087

      15,760

      Change in fair market value of derivative

      (306)

      (1,901)


      4,716

      (3,452)

      Loss on termination of a contract

      (584)

      -


      8,011

      -

      Private placement issuance expense

      -

      (7,530)


      -

      -

      Loss on debt settlement

      -

      (1,458)


      1,136

      (1,501)

      Loss on disposal of assets

      695

      2


      672

      31

      Other expense

      1

      1


      3

      (123)

      Total other (income) expense

      $                3,971

      $           (6,359)


      30,625

      10,715







      Income  (Loss) before taxes

      (6,480)

      6,505


      (27,048)

      (11,393)







      Income taxes

      3,209

      2,777


      10,376

      7,646







      Net income (loss)

      (9,689)

      3,728


      (37,423)

      (19,039)







      Other comprehensive gain (loss) that may be reclassified 






      to profit or loss in subsequent years






      Exchange differences on translation of foreign operations and reporting currency

      1

      (9)


      88

      (42)







      Comprehensive loss

      $          (9,690)

      $         3,737


      $         (37,335)

      $       (19,081)







      Net loss per share






      Basic and diluted - continuing operations






      Basic and diluted - discontinued operations

      $                 (0.03)

      $               0.02


      $                  (0.15)

      $                (0.08)







      Weighted average  number of shares






      Basic number of shares

      254,087,245

      228,628,703


      252,698,567

      228,628,703

      Diluted number of shares

      309,407,433

      275,231,404


      308,498,834

      275,231,404

      CANSORTIUM INC.



      STATEMENTS OF CASH FLOWS



      (USD '000)







       For the years ended December 31, 


      2022

      2021

      Operating activities



      Net loss from continuing operations

      $       (37,146)

      $       (19,004)

      Adjustments to reconcile net loss to net cash provided by (used in) operating activities:



      Unrealized gain (loss) on changes in fair value of biological assets

      9,620

      (14,853)

      Realized (loss) gain on changes in fair value of biological assets

      (2,622)

      21,015

      Share-based compensation

      545

      4,304

      Depreciation and amortization

      13,428

      9,808

      Accretion and interest of convertible debentures

      362

      8,901

      Accretion and interest of term loan

      12,232

      2,700

      Interest income on notes receivable

      (71)

      (266)

      Loss on disposal of assets

      672

      (4)

      Loss on debt settlement

      1,136

      -

      Loss from termination of a contract

      8,011

      -

      Change in fair market value of derivative

      4,716

      (3,452)

      Interest on lease liabilities

      3,612

      2,554

      Deferred tax expense

      (1,273)

      (836)

      Changes in operating assets and liabilities:



      Trade receivable

      (2)

      122

      Inventory

      11,927

      3,490

      Biological assets

      (16,355)

      (14,127)

      Prepaid expenses and other current assets

      404

      (641)

      Right of Use Assets/Liabilities

      197

      -

      Other assets

      (137)

      (207)

      Trade payable

      (1,208)

      3,710

      Accrued liabilities

      (811)

      (1,435)

      Income taxes payable

      11,832

      (6,805)

      Net cash provided by (used in) continuing operating activities

      19,069

      (5,026)

      Net cash used in discontinued activities



      Net cash provided by (used in) operating activities

      19,069

      (5,026)




      Investing activities



      Purchases of property and equipment

      (6,799)

      (21,060)

      Purchase of intangible assets

      -

      (319)

      Payment of notes receivable

      119

      1,419

      Advances for notes receivable 

      (94)

      (2,180)

      Net cash used in continuing investing activities

      (6,774)

      (22,140)

      Net cash provided by discontinued investing activities

      -

      29

      Net cash used in investing activities

      (6,774)

      (22,111)




      Financing activities



      Net proceeds from issuance of shares and warrants

      -

      17,228

      Issuance of warrants for term loan 

      -

      -

      Issuance of warrants from term loan

      -

      9,018

      Issuance of shares for note payable interest and extention expenses

      -

      1,049

      Net proceeds from issuance of convertible debenture and warrants

      4,660

      -

      Net proceeds from issuance of secure term loan

      -

      52,659

      Payment of lease obligations

      (5,771)

      (4,544)

      Return of shares

      -

      -

      Shared issued for interest repayments of notes payable

      -


      Net proceeds from equipment loan

      748

      -

      Exercise of Options

      135

      -

      Exercise of warrants

      -

      1,365

      Issuance of shares for note payable extension 

      162

      -

      Principal repayments of notes payable

      (12,982)

      (43,964)

      Net cash (used in) provided by continuing financing activities

      (13,048)

      32,811

      Net cash provided by discountinued financing activities

      -

      —

      Net cash provided by (used in) financing activities

      (13,048)

      32,811

      Net cash (used in) provided by financing activities

      (13,048)

      32,811

      Effect of foreign exchange on cash

      88

      (42)

      Net (decrease) increase in cash

      (665)

      5,632

      Cash, beginning of period

      9,024

      3,392

      Cash, end of period

      8,359

      9,024

      Cansortium Inc.




      Adjusted EBITDA Calculation




      (USD '000)





      Year Ended


      December 31,

      December 31,



      2022

      2021

      Variance

      Net loss

      $            (37,423)

      $            (19,039)

      $  (18,384)

      Interest expense

      16,087

      15,760

      327

      Income taxes

      10,376

      7,646

      2,730

      Depreciation and amortization

      13,666

      10,685

      2,981

      EBITDA

      $               2,706

      $             15,052

      $  (12,346)










      Year Ended


      December 31,

      December 31,



      2022

      2021

      Variance

      EBITDA

      $               2,706

      $             15,052

      $  (12,346)

      Change in fair market value of derivative

      4,716

      (3,452)

      8,168

      Loss on debt settlement

      1,136

      (1,501)

      2,637

      Private placement issuance expense

      8,011

      -

      8,011

      Share-based compensation

      545

      4,304

      (3,759)

      Change in fair value of biological assets

      6,998

      6,162

      836

      Discontinued operations

      277

      35

      242

      Other non-recurring expense

      675

      (1,007)

      1,682

      Adjusted EBITDA

      $             25,063

      $             19,593

      $      5,470

      SOURCE Cansortium Inc

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.